Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of oroxylin A in preparation of medicine for treating pulmonary fibrosis

A technology for melaleuca and pulmonary fibrosis, which is used in drug combinations, pharmaceutical formulations, plant raw materials, etc.

Active Publication Date: 2021-07-30
NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Our cell and animal experiments have shown that OA has a good effect on improving pulmonary fibrosis, and there is no report on the use of OA to prevent pulmonary fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of oroxylin A in preparation of medicine for treating pulmonary fibrosis
  • Application of oroxylin A in preparation of medicine for treating pulmonary fibrosis
  • Application of oroxylin A in preparation of medicine for treating pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Embodiment 1: The effect of OA on the improvement of bleomycin-induced pulmonary fibrosis in mice

[0036] 1.1 Animals

[0037] Sixty SPF-grade male C57BL / 6J mice, weighing 20-22 g, were provided by Hangzhou Medical College, production license number: SCXK (Zhejiang) 2019-0002.

[0038] 1.2 Drugs and main reagents

[0039]Melaleucain A (gifted by Professor Guo Qinglong of China Pharmaceutical University), bleomycin (Nanjing Jinyibai Biotechnology Co., Ltd., product number HY-17565A), normal saline (Legend Biological Co., Ltd., product number CZ0030), 4% Paraformaldehyde (biosharp, batch number 70071800), antibody TNF-α (ABlconal), IL-1β (Affinity, AF5103), IL-6 (ABlconal), NF-κB (Proteintech, 10745-1-AP); kit TNF -α, IL-1β and IL-6 (purchased from Shanghai Xinle Biotechnology Co., Ltd.).

[0040] 1.3 Main instruments

[0041] Microplate reader, Exposure instrument

[0042] 1.4 Animal grouping

[0043] 60 male C57BL / 6J mice were randomly divided into normal control...

Embodiment 2

[0057] Example 2: In vitro experiment [Observation of OA on TGF-β-induced human myofibroblast activation inhibitory effect (detection of cell proliferation activity)]

[0058] 2.1 The main cells used in the experiment

[0059] MRC-5

[0060] 2.2 Experimental drugs and main reagents

[0061] Melaleucain A (gifted by Professor Guo Qinglong, China Pharmaceutical University), TGF-β (Nanjing Jinyibai Biological Co., Ltd.)

[0062] MEM (Shanghai Yuanpei Biotechnology Co., Ltd.), Fetal Bovine Serum (Nanjing Senbeijia Biotechnology Co., Ltd.), PBS (self-made in the laboratory), Trypsin (BIOFROX, catalog number 1004GR100), MTT (Aladdin), DMSO (Shanghai Lingfeng Chemical Reagent Co., Ltd.), EDTA (BIOSHAP)

[0063] 2.3 Main instruments

[0064] Inverted optical microscope (ZEISS), ultra-clean bench (ESCO BIOTECH), CO2 incubator (ThermoScientific), automatic autoclave (ZEALWAY), ultra-low temperature refrigerator (Haier), pure water instrument (Nanjing Hanlong Laboratory Equipment Co...

Embodiment 3

[0070] Example 3: In Vitro Experiment [OA Cytotoxic Effect on Lung Myofibroblasts (Cytotoxicity Assay)]

[0071] 3.1 The main cells used in the experiment

[0072] MRC-5

[0073] 3.2 Experimental drugs and main reagents

[0074] Melaleucain A (gifted by Professor Guo Qinglong, China Pharmaceutical University), TGF-β (Nanjing Jinyibai Biological Co., Ltd.)

[0075] MEM (Shanghai Yuanpei Biotechnology Co., Ltd.), Fetal Bovine Serum (Nanjing Senbega Biotechnology Co., Ltd.), PBS (self-made in the laboratory), Trypsin (BIOFROX, catalog number 1004GR100), EDTA (BIOSHAP), lactate dehydrogenase Assay kit (Beyontian, product number C10017)

[0076] 3.3 Main instruments

[0077] Inverted optical microscope (ZEISS), ultra-clean bench (ESCO BIOTECH), CO2 incubator (ThermoScientific), automatic autoclave (ZEALWAY), ultra-low temperature refrigerator (Haier), pure water instrument (Nanjing Hanlong Laboratory Equipment Co., Ltd.), refrigerator (Haier), electronic balance (Germany Sarto...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention particularly relates to an application of oroxylin in the preparation of a medicine for treating pulmonary fibrosis. The traditional Chinese medicine monomer has the chemical name of baicalin-6-methyl ether, and the molecular formula of the traditional Chinese medicine monomer is C16H12O5. The research finds that the oroxylin A can improve bleomycin-induced pulmonary fibrosis of mice, after bleomycin-induced pulmonary fibrosis of the mice, the weight of the mice is obviously reduced, and after OA is given, the weight of the mice is increased, so that the OA can be used for preparing the medicine for resisting pulmonary fibrosis.

Description

technical field [0001] The invention relates to a natural product melaleucain A derived from the traditional Chinese medicine Scutellaria baicalensis, in particular to the application of melaleucain A in the preparation of anti-pulmonary fibrosis drugs, and belongs to the field of traditional Chinese medicine pharmacy. Background technique [0002] Pulmonary fibrosis results from a variety of lung injuries, including toxic, autoimmune, drug-induced, infectious, or traumatic injuries, and is characterized by progressive scarring of the lung parenchyma. Pulmonary fibrosis is an age-related disease. Due to the aging population worldwide, the incidence of pulmonary fibrosis also increases, resulting in increased economic burden; and the average survival period after diagnosis of pulmonary fibrosis is only 2.8 Years, much higher than most tumor diseases, was called "tumor-like diseases". At present, the treatment of pulmonary fibrosis is not optimistic, which has aroused great a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/352A61K36/539A61P11/00
CPCA61K31/352A61K36/539A61P11/00
Inventor 郑仕中李余佳郭青龙张峰邵江娟张自力申敏陈利朱韫奇王颖谦
Owner NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com